Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Commentary|Podcasts|August 25, 2023
Pharmacy Focus: Dangers of Drug Diversion for Health Care Professionals
Tom Knight, founder and CEO of Invistics, now part of Wolters Kluwer, discusses the dangers of drug diversion and how this could negatively impact affect patients.
Advertisement
In this week's episode of Pharmacy Focus, Tom Knight, founder and CEO of Invistics, now part of Wolters Kluwer, discusses the dangers of drug diversion and how this could negatively impact affect patients and health care professionals.
Advertisement
Related to this article
Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
The FDA approved lirafugratinib for adults with previously treated, advanced cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement after the REFOCUS trial showed a 46% ORR.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Long-term CASSIOPEIA Registry results show that daratumumab maintenance supports sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
FDA Approves Insulin Efsitora, Once-Weekly Basal Insulin Injection for Adults With T2D
4
Severe Asthma's Effects May Extend Beyond the Lungs, Brain Imaging Study Suggests
5